Literature DB >> 19525866

Defining DIOS and constipation in cystic fibrosis with a multicentre study on the incidence, characteristics, and treatment of DIOS.

Roderick H Houwen1, Hubert P van der Doef, Isabelle Sermet, Anne Munck, Bruno Hauser, Jaroslaw Walkowiak, Eddy Robberecht, Carla Colombo, Maarten Sinaasappel, Michael Wilschanski.   

Abstract

OBJECTIVES: Various definitions for distal intestinal obstruction syndrome (DIOS), meconium ileus equivalent, and constipation in patients with cystic fibrosis (CF) are used. However, an unequivocal definition for DIOS, meconium ileus equivalent, and constipation is preferred. The aims of this study were, therefore, to seek consensus on the definitions for DIOS and constipation in patients with CF and to determine the incidence, characteristics, and treatment of DIOS in a cohort of paediatric patients with CF.
METHODS: During the 2005 European Society for Paediatric Gastroenterology, Hepatology, and Nutrition meeting in Porto a group of paediatric gastroenterologists discussed the definition of DIOS and constipation in CF. Subsequently, all patients younger than or equal to 18 years with complete DIOS according to the definition agreed upon and diagnosed during the years 2001 to 2005 in 8 CF centres were studied.
RESULTS: Distal intestinal obstruction syndrome was defined as an acute complete or incomplete faecal obstruction in the ileocaecum, whereas constipation was defined as gradual faecal impaction of the total colon. Fifty-one episodes of DIOS in 39 patients were recorded, giving an overall incidence of 6.2 (95% confidence interval, 4.4-7.9) episodes per 1000 patient-years. Of the 39 patients with DIOS, 20% experienced a relapse, 92% were pancreatic insufficient, 44% had a history of meconium ileus at birth, and 82% had a severe genotype. Conservative treatment was effective in 49 of 51 DIOS episodes (96%).
CONCLUSIONS: The European Society for Paediatric Gastroenterology, Hepatology, and Nutrition CF Working Group definitions of DIOS and constipation in CF are specific and make a clear distinction between these 2 entities. The incidence of DIOS in the present study was considerably higher than reported previously.

Entities:  

Mesh:

Year:  2010        PMID: 19525866     DOI: 10.1097/MPG.0b013e3181a6e01d

Source DB:  PubMed          Journal:  J Pediatr Gastroenterol Nutr        ISSN: 0277-2116            Impact factor:   2.839


  42 in total

Review 1.  Gastrointestinal Manifestations of Cystic Fibrosis.

Authors:  Thomas Kelly; James Buxbaum
Journal:  Dig Dis Sci       Date:  2015-02-04       Impact factor: 3.199

Review 2.  Beyond pancreatic insufficiency and liver disease in cystic fibrosis.

Authors:  Stephanie Demeyer; Kris De Boeck; Peter Witters; Katrien Cosaert
Journal:  Eur J Pediatr       Date:  2016-04-07       Impact factor: 3.183

3.  Intraoperative intraluminal injection of N-acetylcysteine allowing treatment of distal intestinal obstruction syndrome without the need for enterotomy.

Authors:  Nicholas Js Chilvers; James Wheeler
Journal:  BMJ Case Rep       Date:  2018-05-16

Review 4.  Precision Genomic Medicine in Cystic Fibrosis.

Authors:  Eugene H Chang; Joseph Zabner
Journal:  Clin Transl Sci       Date:  2015-06-15       Impact factor: 4.689

5.  Study design considerations for evaluating the efficacy and safety of pancreatic enzyme replacement therapy in patients with cystic fibrosis.

Authors:  Michael W Konstan; Drucy Borowitz; Nicole Mayer-Hamblett; Carlos Milla; Leslie Hendeles; Susan Murray; Richard A Kronmal; Susan Casey; Lynn M Rose; Wayne J Morgan; Bonnie W Ramsey
Journal:  Clin Investig (Lond)       Date:  2013-08

Review 6.  The gastrointestinal mucus system in health and disease.

Authors:  Malin E V Johansson; Henrik Sjövall; Gunnar C Hansson
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-03-12       Impact factor: 46.802

7.  Intestinal CFTR expression alleviates meconium ileus in cystic fibrosis pigs.

Authors:  David A Stoltz; Tatiana Rokhlina; Sarah E Ernst; Alejandro A Pezzulo; Lynda S Ostedgaard; Philip H Karp; Melissa S Samuel; Leah R Reznikov; Michael V Rector; Nicholas D Gansemer; Drake C Bouzek; Mahmoud H Abou Alaiwa; Mark J Hoegger; Paula S Ludwig; Peter J Taft; Tanner J Wallen; Christine Wohlford-Lenane; James D McMenimen; Jeng-Haur Chen; Katrina L Bogan; Ryan J Adam; Emma E Hornick; George A Nelson; Eric A Hoffman; Eugene H Chang; Joseph Zabner; Paul B McCray; Randall S Prather; David K Meyerholz; Michael J Welsh
Journal:  J Clin Invest       Date:  2013-05-08       Impact factor: 14.808

8.  Intestinal obstruction secondary to adhesions in an infant with cystic fibrosis.

Authors:  Mohammed Jawad; Gillian Klafkowski; Warren Lenney; Francis J Gilchrist
Journal:  BMJ Case Rep       Date:  2013-07-29

Review 9.  Cystic fibrosis from the gastroenterologist's perspective.

Authors:  Chee Y Ooi; Peter R Durie
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-01-21       Impact factor: 46.802

10.  Gastrointestinal Manifestations of Cystic Fibrosis.

Authors:  Sabina Sabharwal
Journal:  Gastroenterol Hepatol (N Y)       Date:  2016-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.